Clinical Trials
10 trialsNCT05768932 2026-03-27
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
NCT04577963 2025-07-14
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT06538896 2024-11-26
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT04914390 2024-01-22
NeoATCT
Sichuan Provincial People's Hospital
Phase 2 Unknown
NCT04734262 2023-11-18
SPARK
Fudan University
Phase 2 Unknown
NCT05809895 2023-07-24
AdvanTIG-211
Novartis
Phase 2 Withdrawn
NCT05746728 2023-04-06
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Tongji Hospital
Phase 1/2 Unknown
NCT04501523 2023-02-21
Apollo
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT04913571 2021-06-04
TEMPLATE
Fudan University
Phase 2 Unknown